News | February 22, 2023
Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Agasta Software is engaged in research, development and commercialization of medical devices
Cipla has received 8 inspectional observations in Form 483
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Subscribe To Our Newsletter & Stay Updated
